Abstract

COMPARATIVE EFFICACY OF TWO ORAL APRAMYCIN FORMULATION (NEOVE APRAMYCIN® AND APRABIOPHAR®) AGAINST EXPERIMENTAL INFECTION WITH ESCHERICHIA COLI IN BROILER BREEDERS

Ashraf El-Komy* and Mohamed Aboubakr

ABSTRACT

This study was conducted to assess the efficacy of apramycin (Neove Apramycin® and Aprabiophar®) in controlling the adverse effects of experimentally induced colibacillosis in broiler breeders. Two hundred, one-day old broiler breeder chicks were used and randomly allocated into three experimental groups; group (1) uninfected-untreated, group (2) infected-untreated, group (3) infected-treated with apramycin (Neove Apramycin)® in the drinking water and group (4) infected-treated with apramycin (Aprabiophar)® in the drinking water. The drug was given at dose level of 25 mg apramycin /kg b.wt/day for 5 consecutive days. Experimental colibacillosis was induced at 21-day of age by IM inoculation of Escherichia coli (E.coli) serotype O78: K80. Clinical signs, mortalities, mean lesion scores, performance including body weight and feed conversion efficiency were recorded and evaluated. The Results showed that infected-apramycin treated chickens had less pronounced clinical signs, significant lower mortalities, higher body weight and better feed conversion than infected-untreated birds. In conclusion, apramycin administration (Neove Apramycin® and Aprabiophar®) at 25 mg apramycin/kg b.wt /day for 5 consecutive days is efficacious for the treatment of colibacillosis in broiler breeders evident by improvement of all investigated parameters. There was no significant changes between Neove Apramycin® and Aprabiophar® and both products can be used as interchangeable drug in veterinary medicine practice especially in poultry.

Keywords: .